Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Interim results of MOGN's ongoing open label Phase II trial of 50 patients with advanced pancreatic
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury